title: [Cognitive-behavioural therapy in early psychosis: an open study in a clinical setting].
abstract: OBJECTIVE
  Meta-analysis results confirm that cognitive-behavioural therapy in psychosis (CBTp) is efficient for persistent symptoms. However, external validity remains unexplored. CBTp in early psychosis (in the first 5 years after diagnosis) seems especially relevant, given a possible impact on long-term course. However, the few studies that experimented with CBTp with this population had poor results. They all introduced therapy during an acute psychotic phase and most of them performed a limited number of sessions. Therefore, our introductory open study aimed to evaluate the efficiency of a 25-session Australian CBTp program, introduced during a stable phase in Quebec patients with early psychosis.
  
  
  METHODS
  The Active Cognitive Psychotherapy for Early Psychosis program was offered to 20 patients aged 14 years or older, at a rate of 1 weekly session during 6 months.
  
  
  RESULTS
  The acceptance rate was 75%, the mean session compliance rate was 84%, and participants were satisfied with the program. Pre- and post-CBTp analyses indicated statistically significant improvements of psychotic symptomatology, which were maintained at 6-month follow-up. Self-criticism improvement was also statistically significant, post-CBTp.
  
  
  CONCLUSIONS
  CBTp seems to be appropriate in our clinical settings, including with adolescents. Moreover, the treatment dosage used seems to foster session compliance.
authors.affiliation: Programme de Dépistage et intervention précoce des psychoses, Centre de pédopsychiatrie de Québec, Centre hospitalier universitaire de Québec, 1 avenuedu Sacré-Coeur, Québec, QC. mj.marois@mail.chuq.qc.ca
authors.forename: Marie-Josée
authors.initials: MJ
authors.lastname: Marois
authors.forename: Nathalie
authors.initials: N
authors.lastname: Gingras
authors.forename: Martin D
authors.initials: MD
authors.lastname: Provencher
authors.forename: Chantal
authors.initials: C
authors.lastname: Mérette
authors.forename: Claudia
authors.initials: C
authors.lastname: Emond
authors.forename: Julie
authors.initials: J
authors.lastname: Bourbeau
authors.forename: Valérie
authors.initials: V
authors.lastname: Jomphe
authors.forename: Marc-André
authors.initials: MA
authors.lastname: Roy
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D003702:Delusions / Q000175:diagnosis / Q000523:psychology / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000175:diagnosis / Q000523:psychology / Q000628:therapy*; D011792:Quebec; D012559:Schizophrenia / Q000175:diagnosis / Q000628:therapy*; D012565:Schizophrenic Psychology; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents